{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:23:45Z","timestamp":1761578625243},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title \/>\n                  <jats:p>A challenge in counseling patients with a family history suggesting a hereditary cancer syndrome is deciding which genetic tests or panels to order. In this article, we discuss the identification of multiple familial mutations through genetic counseling and panel testing. For patients meeting National Comprehensive Cancer Network criteria for clinical genetic testing, providers should consider expanded panels to provide a more complete assessment of one's genetic risk. The continued use of expanded panel testing in the clinical setting will help inform optimal management of cancer patients, as well as the management of their unaffected family members. The mutation discovered in this case was in the ATM gene. The clinical significance of the mutation, potential therapeutic targets, and proper clinical management are discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>With single-site genetic testing, there is the potential to miss hereditary genetic syndromes that can be managed clinically. Between 4% and 6% of hereditary breast and ovarian cancer syndromes are caused by genes other than BRCA1 and BRCA2. ATM is a DNA mismatch repair gene associated with double-stranded DNA break repair and cell cycle checkpoint arrest. The risk of developing female breast cancer by age 50 and by age 80 in ATM heterozygotes is 9% and 17%\u201352%, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0372","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T18:11:59Z","timestamp":1518631919000},"page":"393-396","source":"Crossref","is-referenced-by-count":1,"title":["The Perils of Single-Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next-Generation Sequencing"],"prefix":"10.1093","volume":"23","author":[{"given":"Nicole","family":"Casasanta","sequence":"first","affiliation":[{"name":"School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Stark","sequence":"additional","affiliation":[{"name":"Medical Faculty Associates, The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"McHenry","sequence":"additional","affiliation":[{"name":"Medical Faculty Associates, The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Biagi","sequence":"additional","affiliation":[{"name":"Medical Faculty Associates, The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kaltman","sequence":"additional","affiliation":[{"name":"Medical Faculty Associates, The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2021122510435703700_onco12365-bib-0001","year":"2017"},{"key":"2021122510435703700_onco12365-bib-0012","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3324\/haematol.2009.021626","article-title":"Constitutional mismatch repair-deficiency syndrome","volume":"95","author":"Wimmer","year":"2010","journal-title":"Hematologica"},{"key":"2021122510435703700_onco12365-bib-0002","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/humu.23052","article-title":"Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of Lynch syndrome or constitutional mismatch repair deficiency syndrome","volume":"37","author":"Klift","year":"2016","journal-title":"Hum Mutat"},{"key":"2021122510435703700_onco12365-bib-0007","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.currproblcancer.2017.02.009","article-title":"Inherited mutations in DNA repair genes and cancer risk","volume":"41","author":"Laorden-Romero","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"2021122510435703700_onco12365-bib-0009","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2021122510435703700_onco12365-bib-0011","author":"National Cancer Institute","year":"2006"},{"key":"2021122510435703700_onco12365-bib-0010","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: Therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2021122510435703700_onco12365-bib-0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10549-016-4003-9","article-title":"Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care","volume":"160","author":"Graffeo","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122510435703700_onco12365-bib-0003","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/gepi.21971","article-title":"Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk","volume":"40","author":"Marabelli","year":"2016","journal-title":"Genet Epidemiol"},{"key":"2021122510435703700_onco12365-bib-0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","article-title":"Health risks for ataxia-telangiectasia mutated heterozygotes: A systematic review, meta-analysis and evidence-based guidelines","volume":"90","author":"Os","year":"2016","journal-title":"Clin Genet"},{"key":"2021122510435703700_onco12365-bib-0006","author":"Weitzel","year":"2015"},{"key":"2021122510435703700_onco12365-bib-0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc970","article-title":"The Fanconi anemia\/BRCA pathway","volume":"3","author":"D'Andrea","year":"2003","journal-title":"Nat Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0372","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/393\/41915272\/oncolo_23_4_393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/393\/41915272\/oncolo_23_4_393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:45:23Z","timestamp":1640429123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/4\/393\/6439564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0372","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2018,2,14]]}}}